The Lancet Haematology @TheLancetHaem Twitter profile

Pinned Tweet

The Lancet Haematology

15 days

Our June issue is live now! Cover art by @samfalc inspired by the lon-term data of the REACH trial: optimising hydroxyurea dose for children with #sicklecell anaemia in sub-Saharan Africa ( #freeaccess ) Explore the content at

1

3

14

Last Seen Profiles

@Benjamin_Adlard

@YusufKilic0_0

@AlfredoMolanoB

@hj_clockbox

@LatriceSat73284

@SoihanP

@Paob31

@azxyc

@yarpolyanitsa

@Halfspace_kop

@pengen_stw

@UMNSDS

@jsuis1dz

@SJackson26767

@Cab_Virgen

@aabdoallah

@Raimuwolf

@peugeot_ng

@NikilisRBX

@computerwarez

@PetawayJoe39543

@wangsen578

@onlyjohnnyd

@michalhay

@EefeyPrecious

@YoniAshar

@Pecintastw4050

@BrianCLambeth

@FaithNwach41156

@pent_Mosa

@Head8cke

@harupyon_hirata

@safemoonroofer

@Fivebanger

@jonot04

@kepnersaveries

The Lancet Haematology

@TheLancetHaem

10 months

"The existence of two acute myeloid leukaemia classification systems...is concerning... and threatens the ability to... deliver appropriate... management strategies" NEW Viewpoint—Standardising acute myeloid leukaemia classification systems #leusm

2

108

279

The Lancet Haematology

@TheLancetHaem

2 years

Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin? NEW Viewpoint by Michael J Hochman and Amy E DeZern @AmyDeZern #MDSsm

2

95

213

The Lancet Haematology

@TheLancetHaem

2 years

“As a society committed to recognising and transforming gender inequalities, it is time to remove sex-based thresholds for one of the most common global human afflictions” #anaemia ICYMI Comment by @acweyand @PTMcGann @sholzberg . Free w/reg until Jan 31

Sex specific definitions of anaemia contribute to health inequity and sociomedical injustice

Anaemia, as defined by WHO, is the pathological condition in which the number of red blood cells or haemoglobin within them is insufficient to meet the body's physiological oxygen carrying needs. The...

www.thelancet.com

4

47

158

The Lancet Haematology

@TheLancetHaem

1 year

"The needle would move forward more efficiently when academic medicine equally recognises... clinicians... who dedicate their careers to honing their skills and... impart their wisdom onto the next generation of physicians" Art of Medicine by @THilalMD

In the trenches

When I look back at the most influential clinicians who have taught me clinical reasoning and how to interact with patients, they had several traits in common. They often were enormously respected by...

www.thelancet.com

4

43

155

The Lancet Haematology

@TheLancetHaem

9 months

"The existence of two acute myeloid leukaemia classification systems...is concerning... and threatens the ability to... deliver appropriate... management strategies" ICYMI Viewpoint—Standardising acute myeloid leukaemia classification systems #leusm

0

55

152

The Lancet Haematology

@TheLancetHaem

5 months

NEW: Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of @TheEBMT #bmtsm #GVHD

0

63

155

The Lancet Haematology

@TheLancetHaem

4 years

In today’s late breaking abstract session at @EHA_Hematology Virtual, Courtney DiNardo presents results of the phase 3 RCT testing venetoclax plus azacitidine vs azacitidine in patients with AML ineligible for intensive therapy (VIALE-A) #EHA2020

2

64

150

The Lancet Haematology

@TheLancetHaem

1 year

Ahead of #WorldSickleCellDay #WSCD23 we are publishing the first detailed global estimates on the burden of #sicklecell disease Read it #openaccess The authors show that mortality linked to #sicklecell disease is higher than previously described🧵

2

64

111

The Lancet Haematology

@TheLancetHaem

3 years

NEW: Jenneke Leentjens and colleagues give their views on what we have learned and what remains to be learned about coagulopathy and antithrombotic agents in COVID-19 after 1 year. #COVID19

4

53

104

The Lancet Haematology

@TheLancetHaem

1 year

NEW: Defibrotide did not show a benefit in the prophylaxis of sinusoidal obstruction syndrome compared with best standard of care alone in the HARMONY phase 3 trial #bmtsm

3

41

97

The Lancet Haematology

@TheLancetHaem

7 months

New: Final results from the phase 3 HOVON/SAKK trial, comparing R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma

0

41

90

The Lancet Haematology

@TheLancetHaem

3 years

Now OF: Hagop Kantarjian and colleagues review available targeted therapies for AML. #leusm

0

24

88

The Lancet Haematology

@TheLancetHaem

1 year

In the issue now: the chemotherapy-free combination of ponatinib and blinatumomab resulted in high rates of complete molecular response in newly diagnosed and r/r Ph-positive ALL @MDAndersonNews

1

25

86

The Lancet Haematology

@TheLancetHaem

3 years

NEW Review—Understanding moderate to severe drug–drug interactions between novel targeted #hemonc therapies and triazole antifungal agents, which are essential for prophylaxis & long-term treatment of fungal infections #leusm #lymsm #mpnsm

1

47

85

The Lancet Haematology

@TheLancetHaem

11 months

NEW: with over 5 years of follow-up, sorafenib maintenance is associated with improved outcomes compared w/ non-maintenance in patients w/ FLT3-ITD AML undergoing allogeneic HSCT in a multicentre, randomised, ph 3 trial #leusm #bmtsm

0

42

83

The Lancet Haematology

@TheLancetHaem

7 months

NEW: 10-day decitabine vs 3+7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial #bmtsm #leusm

1

26

76

The Lancet Haematology

@TheLancetHaem

7 months

Germline predisposition traits in allogeneic transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of @TheEBMT #bmtsm #leusm #mdssm

1

25

82

The Lancet Haematology

@TheLancetHaem

2 years

Our first issue of 2022 is live! 🎉 Featuring trials in #sicklecell & #GVHD , a study on #QoL in #mpnsm , a review on drug-drug interactions between #hemonc targeted therapies & antifungals, #VITT and more!

1

18

76

The Lancet Haematology

@TheLancetHaem

4 years

NEW research—Findings from a cross-sectional study suggest endotheliopathy is present in #COVID -19 and is likely to be associated with critical illness and death #COVID19

3

35

75

The Lancet Haematology

@TheLancetHaem

3 years

ICYMI: @DrHKantarjian and colleagues review available targeted therapies for AML. #leusm

0

26

77

The Lancet Haematology

@TheLancetHaem

1 year

In the issue now: brentuximab vedotin plus nivolumab was highly active post-autologous HSCT consolidation for patients w/ high-risk r/r Hodgkin lymphoma #lymsm

1

19

72

The Lancet Haematology

@TheLancetHaem

3 years

New Editorial discussing the latest developments on #COVID19 coagulopathy

1

31

69

The Lancet Haematology

@TheLancetHaem

3 years

Our July issue is live! Featuring highlights from #EHA2021 , trials in #hemophilia and AML, meta-analysis in #anemia , Review on long-term toxicity in AML, Viewpoint on #COVID19 coagulopathy, and pieces on #SickleCell and including women in research. #leusm

3

23

70

The Lancet Haematology

@TheLancetHaem

2 years

Now OF: In a single-arm, multicentre, ph 2 study of venetoclax plus 3+7 daunorubicin and cytarabine in adults with AML, the composite complete remission rate after one cycle was 91% (95% CI 76–98; 30 of 33 patients) #leusm

2

30

71

The Lancet Haematology

@TheLancetHaem

11 months

HTLV-1 infects 10–20 million people globally and is associated with lifelong infection and immune suppression, resulting in adult T-cell #leukaemia or #lymphoma in 5% of cases. There are no preventive or curative treatments #leusm #lymsm NEW Review

0

25

69

The Lancet Haematology

@TheLancetHaem

4 years

Guillermo García-Manero discusses recent advances in AML and MDS therapy and treatment algorithms used at MD Anderson. Determining the genetic background is key. #EBMT20Virtual

3

31

69

The Lancet Haematology

@TheLancetHaem

2 years

"The pathophysiology of malignancy-associated HLH is not well understood, and distinguishing pathological immune activation from... abnormalities seen in cancer and cancer treatment is challenging" NEW Review on the emerging diagnostic tools #hemonc

1

27

69

The Lancet Haematology

@TheLancetHaem

4 years

“Assessing venous thromboembolism and bleeding risks regularly is essential... we found that patients with COVID-19 with a high risk of venous thromboembolism had poorer outcomes” NEW—comment by Wang and colleagues from China #COVID19 #VTE #anticoag

1

53

68

The Lancet Haematology

@TheLancetHaem

5 years

NEW research—Catheter-directed #thrombolysis does not change the risk of post-thrombotic syndrome 1 year after acute iliofemoral #DVT compared with standard therapy alone: results from the CAVA trial #VTE

2

29

65

The Lancet Haematology

@TheLancetHaem

4 months

"The presence of vacuoles is a key feature of VEXAS syndrome, however, its mere observation is not specific" In this Viewpoint, authors describe several clues to support the diagnosis of VEXAS syndrome in the presence of vacuolated bone marrow progenitors

0

18

62

The Lancet Haematology

@TheLancetHaem

3 years

Our June issue is live! Featuring a Viewpoint on race-based reference ranges, In Focus pieces for #InternationalNursesDay , trials in #lymsm , and a trial, Review of #CARTcell therapy, and Comment on first response to #COVID19Vaccine in #mmsm

3

19

64

The Lancet Haematology

@TheLancetHaem

4 years

Today is #WorldSickleCellDay . To help raise awareness of this public health problem we look at several aspects of the disease (thread; free w/reg until July 6). First, the intersection of #sicklecell disease & global health priorities⬇️

2

51

60

The Lancet Haematology

@TheLancetHaem

6 months

Updated consensus guidelines on allogeneic HSCT for #myelofibrosis by @TheEBMT & the European LeukemiaNet #bmtsm #mpnsm 💡As evidence-based guidance is scarce, these recommendations might help clinicians and patients in shared decision making

2

28

63

The Lancet Haematology

@TheLancetHaem

3 years

"Recommendations regarding management of essential thrombocythaemia rely on studies done before the discovery of the CALR mutation" NEW: The European LeukemiaNet presents the first consensus recommendations to manage patients with CALR-mutated ET #mpnsm ➡️

0

29

61

The Lancet Haematology

@TheLancetHaem

4 years

"On the basis of this management, we saw no SARS-CoV-2 infection in children with haematological malignancies" NEW comment—Strategic plan for management of #COVID19 in #paediatric #haematology and #oncology departments by Yulei He and colleagues

1

40

60

The Lancet Haematology

@TheLancetHaem

3 years

NEW: In a multicentre, open-label, randomised, controlled, phase 2 trial, the combination of all-trans retinoic acid and high-dose dexamethasone was safe and active in newly diagnosed patients with primary immune thrombocytopenia. #BleedingDisorders

1

24

59

The Lancet Haematology

@TheLancetHaem

3 years

Our Oct issue is live! It includes our Series on haematological care in sub-Saharan Africa, trials in immune thrombocytopenia and ALL, and research on #COVIDVaccine responses in HSCT recipients. #anemia #BleedingDisorders #leusm #SickleCell #transfusion

1

26

60

The Lancet Haematology

@TheLancetHaem

8 months

13 international guidelines provide recommendations on pulmonary embolism... #VTE #PE #thrombosis This Review compares guidelines on each facet of the diagnosis of pulmonary embolism and provides a synthesis on the most common recommendations

0

20

57

The Lancet Haematology

@TheLancetHaem

2 years

NOW OF: In a single-centre, single-arm, ph 2 trial, 33 (87%) of 38 patients with ND and 11 (79%) of 13 with R/R Ph-positive ALL and 2 (33%) of 6 patients with blast-phase CML had a complete molecular response with ponatinib and blinatumomab. #leusm

1

20

55

The Lancet Haematology

@TheLancetHaem

3 years

NEW— #COVID19 vaccination in patients with multiple myeloma: a consensus of the European #Myeloma Network #mmsm #CovidVaccine

1

29

53

The Lancet Haematology

@TheLancetHaem

9 months

NEW—the final analysis of GRIFFIN showed that the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone in transplantation-eligible pts w/ newly diagnosed multiple myeloma improved depth of response and PFS, but not OS #mmsm

0

30

53

The Lancet Haematology

@TheLancetHaem

3 years

NEW: In a 5-year update of the HD18 phase 3 trial of PET-guided eBEACOPP in Hodgkin lymphoma, PFS was >90% with 6 cycles of eBEACOPP after positive PET-2, and 4 cycles was non-inferior in terms of PFS to 8 or 6 cycles in PET-2-negative disease #lymsm

1

22

53

The Lancet Haematology

@TheLancetHaem

8 months

NEW online: results from the ph2 MASTER trial suggest that minimal residual disease response-adapted therapy with Dara-KRd consolidation provides a pathway for treatment cessation in most patients with newly diagnosed multiple myeloma #mmsm

1

16

51

The Lancet Haematology

@TheLancetHaem

4 years

"There is still much to be learned about this coagulopathy, but the fast and ongoing collaboration worldwide makes for a hopeful outcome" Our new Editorial discusses the rapidly evolving story of #COVID19 -associated #coagulopathy

0

20

49

The Lancet Haematology

@TheLancetHaem

5 months

NEW: results from a randomised, ph3 trial show that extending letermovir prophylaxis to 200 days following HSCT is efficacious and safe in reducing the incidence of late clinically significant cytomegalovirus infection in patients at risk #bmtsm

Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic...

Extending the duration of letermovir prophylaxis to 200 days following HSCT is efficacious and safe in reducing the incidence of late clinically significant cytomegalovirus infection in patients at...

www.thelancet.com

1

26

55

The Lancet Haematology

@TheLancetHaem

5 years

Therapy for #lymphoma has made many advances through the years, but there is still so much to be done, including making sure that we capture the full effect of treatment on patients. #WorldCancerDay #adverseevents

0

25

50

The Lancet Haematology

@TheLancetHaem

3 years

Our The Arts piece discusses perhaps one of the earliest medical illustrations of an aggressive extranodal natural killer T-cell lymphoma, nasal type in a 19th century Qing Dynasty painting #lymsm

0

13

49

The Lancet Haematology

@TheLancetHaem

4 years

Join our webinar in which the authors of our new joint Series with @TheLancetHIV discuss work on haematological cancers providing insights into a potential cure for HIV. All you have to do is register here: and join us on Thurs, Aug 13 at 4:00pm BST.

0

20

46

The Lancet Haematology

@TheLancetHaem

6 years

Current methods of reporting #adverseevents for #bloodcancers often fail to identify important delayed, chronic, or cumulative side-effects that can affect patients substantially, graphical displays could be more accurate - new #lancethaemcommission #EHA23

1

33

47

The Lancet Haematology

@TheLancetHaem

2 years

#SOHO2022 Fadi Haddad presents updates from a ph 2 study of blinatumomab + ponatinib in Ph-positive #ALL . CMR rate was 85% for newly diagnosed and 79% for R/R disease, and ORR was 96% and 92%.

0

20

49

The Lancet Haematology

@TheLancetHaem

8 months

“We’ve got more people surviving cancer... Now more than ever, we need recognition for more rehabilitation services for these patients” New Profile on @Orla_McCourt #rehabilitation #haematology @uclh

Orla McCourt—making space for proactive rehabilitation in haematology

“I have distinct patients that stand out in my mind, I still remember them”, Orla McCourt said of her early years training as a physiotherapist. A clinical academic physiotherapist at University...

www.thelancet.com

1

11

48

The Lancet Haematology

@TheLancetHaem

3 years

Our May issue is live! Featuring an Editorial on #COVID19vaccine & #thrombosis , trials in #SickleCell and paroxysmal nocturnal haemoglobinuria, a review of polyclonal hypergammaglobulinaemia, and more. #COVID19 #Hemophilia #lymsm #tcellrx

1

22

47

The Lancet Haematology

@TheLancetHaem

1 year

NEW research—Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for children and young adults w/ newly diagnosed T-cell ALL: results of the nationwide, phase 2, ALL-T11 trial 🇯🇵 #leusm

1

20

46

The Lancet Haematology

@TheLancetHaem

6 months

NEW: a cohort study on CCUS suggests high-risk mutations and their number are predictive of survival warranting clinical surveillance & advises mutation analysis in patients with available bone marrow samples #cytopenias

0

22

48

The Lancet Haematology

@TheLancetHaem

4 years

Our August issue is out: Featuring endotheliopathy in #COVID19 , selinexor in #MDS , #VTE and mortality, #HIV -associated Burkitt lymphoma, & more!

2

14

46

The Lancet Haematology

@TheLancetHaem

1 year

NEW: intensive chemo with or without gemtuzumab ozogamicin in patients with NPM1-mutated AML (AMLSG 09–09, phase 3 trial): while the primary endpoints of the trial (EFS & OS) were not met, an anti-leukaemic activity was shown by lower relapse #leusm

2

20

48

The Lancet Haematology

@TheLancetHaem

4 years

NEW research—A retrospective study from Italy in 536 pts with haematological malignancies & #COVID19 adds to the evidence that these patients have worse outcomes & highlights the need for infection prevention strategies #hemonc #leusm #lymsm #mmsm

1

25

48

The Lancet Haematology

@TheLancetHaem

3 years

NEW Review on #CARTcell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? #lymsm

0

25

46

The Lancet Haematology

@TheLancetHaem

2 years

Results from the Highlow RCT presented by @MiddeldorpS at #ISTH2022 comparing intermediate vs low dose LMWH in pregnant women who have had previous VTE. Antenatal no difference between dose for VTE, postpartum intermediate dose may be more protective.

1

22

44

The Lancet Haematology

@TheLancetHaem

11 months

The Lancet Haematology Commission on #SickleCellDisease has now been published—aiming to achieve greater political commitment, investment, and partnerships to improve the lives of patients with sickle cell disease globally in the next decades.

1

20

45

The Lancet Haematology

@TheLancetHaem

3 years

NEW Viewpoint—Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions #bmtsm

1

32

46

The Lancet Haematology

@TheLancetHaem

2 years

“As a society committed to recognising and transforming gender inequalities, it is time to remove sex-based thresholds for one of the most common global human afflictions” #anaemia #WomensHealth NEW comment by @acweyand @PTMcGann @sholzberg

Sex specific definitions of anaemia contribute to health inequity and sociomedical injustice

Anaemia, as defined by WHO, is the pathological condition in which the number of red blood cells or haemoglobin within them is insufficient to meet the body's physiological oxygen carrying needs. The...

www.thelancet.com

1

17

44

The Lancet Haematology

@TheLancetHaem

4 years

“Available evidence suggests that the coagulopathy associated with COVID-19 is a combination of low-grade DIC and localised pulmonary thrombotic microangiopathy” New comment by @MarcelLevi , Jecko Thachil, Toshiaki Iba, @JerroldLevy

1

27

44

The Lancet Haematology

@TheLancetHaem

1 year

NEW: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy showed promising activity in terms of PFS in older patients with B-cell ALL: results of a phase 2 trial @MDAndersonNews #leusm

1

10

44

The Lancet Haematology

@TheLancetHaem

2 years

NEW research—Azacitidine with venetoclax is safe & shows encouraging activity in patients with high-risk MDS or CMML: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study #MDSsm

2

19

44

The Lancet Haematology

@TheLancetHaem

2 years

Despite continued improvement in outcomes, infectious complications remain a clinically significant cause of mortality in patients with multiple myeloma NEW Consensus paper provides a template from which an individualised patient plan can be derived #mmsm

0

18

44

The Lancet Haematology

@TheLancetHaem

3 years

NEW: results from the phase 3, GENUINE trial show the addition of ublituximab to ibrutinib improves overall response without affecting the safety profile of ibrutinib monotherapy in patients w/ r/r high-risk chronic lymphocytic leukaemia #CLL #leusm

0

15

43

The Lancet Haematology

@TheLancetHaem

3 years

Mohamad Mohty discusses the importance of pre-transplantation remission status in terms of outcomes following transplantation #EBMT21

0

13

40

The Lancet Haematology

@TheLancetHaem

3 years

NEW research—A @CIBMTR study in 318 patients HSCT recipients diagnosed with #COVID19 adds to the evidence these patients have poor overall survival & identifies risk factors associated with death from COVID-19 #bmtsm

1

22

42

The Lancet Haematology

@TheLancetHaem

4 years

In today’s plenary session, Ayalew Tefferi discusses prognostication and management of essential thrombocythemia, including the genetic mutations seen in ET and the potential need to examine the bone marrow when diagnosing the condition #SOHO2020

1

19

41

The Lancet Haematology

@TheLancetHaem

1 year

Today is #WorldSickleCellDay #WSCD23 #SickleCellDisease has been a priority for this Journal in the past years and the result is a Commission that will be officially launched on July 12, 9.30 – 11am East Africa Time at a hybrid event ⬇️ Register at

0

19

39

The Lancet Haematology

@TheLancetHaem

7 months

ICYMI: Final results from the phase 3 HOVON/SAKK trial suggests DA-EPOCH-R might be a less toxicity alternative to R-CODOX-M/R-IVAC in patients with newly diagnosed Burkitt lymphoma #lymsm

1

16

42

The Lancet Haematology

@TheLancetHaem

3 years

Our March issue is out! Featuring articles on #COVID19 outcomes in #bmt recipients, the low-PV trial, excess risk of infection with #CARTcell therapy, and more! #mpnsm #bmtsm ➡️

2

14

41

The Lancet Haematology

@TheLancetHaem

4 years

Is auto-transplant standard of care for eligible patients with multiple myeloma? #mmsm #EBMT20Virtual Francesca Gay argues auto-transplant is still standard. @Mohty_EBMT adds that delaying transplant might mean 30% of patients missing the chance of improved outcomes

0

21

41

The Lancet Haematology

@TheLancetHaem

1 year

“[CAR-T ARI-0001 distribution] would be a boost to the development of CAR T-cell therapies in other academic institutions, a fundamental aspect to promote innovation in advanced therapies in Europe” Profile on Álvaro Urbano-Ispizua @hospitalclinic #celltx

Álvaro Urbano-Ispizua—a more accessible last chance for patients

Advanced haematological malignancies can have among the bleakest prognoses, with life expectancies reduced to weeks instead of months or years. Recent drastic improvements have occurred, though,...

www.thelancet.com

0

14

40

The Lancet Haematology

@TheLancetHaem

7 months

13 international guidelines provide recommendations on pulmonary embolism... #VTE #PE #thrombosis In the Issue, a Review compares guidelines on each facet of the diagnosis of pulmonary embolism and provides a synthesis on the most common recommendations

1

17

40

The Lancet Haematology

@TheLancetHaem

3 years

NEW Viewpoint by @Erik_Klok_MD , @MPaiMD , Menno Huisman & @ProfMakris discussing the epidemiology, pathophysiology, and optimal diagnostic and therapeutic management of vaccine-induced immune thrombotic thrombocytopenia #VITT #COVID19Vaccine

0

16

40

The Lancet Haematology

@TheLancetHaem

3 years

A series of papers discussing responses to SARS-CoV-2 vaccination in people with haematological malignancies are now available OF. #COVID19 #COVID19Vaccine

1

15

41

The Lancet Haematology

@TheLancetHaem

4 years

There are many outstanding questions with transplantation in patients with newly diagnosed multiple myeloma, but Prof María-Victoria Mateos delivers a comprehensive overview of the topic and future directions at the opening keynote lecture at #EBMT20Virtual

1

28

40

The Lancet Haematology

@TheLancetHaem

3 years

NEW: Findings from a post-hoc analysis of pooled data from five clinical trials support the use of anti-CD19 CAR T-cell therapies for patients with CNS relapsed or refractory B-cell acute lymphocytic leukaemia. #leusm #CARTcell

1

9

40

The Lancet Haematology

@TheLancetHaem

3 years

NEW research: venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed AML or high-risk MDS: a cohort from a phase 2 trial @MDAndersonNews #leusm #mdssm

1

15

40

The Lancet Haematology

@TheLancetHaem

4 years

Profile on Vania Hungria—treating myeloma with restricted resources @dra_v_hungria #mmsm “I had the enormous privilege of meeting Vania Hungria almost 20 years ago... She had already started her fight for fair access to drugs in Latin America” says @mvmateos

3

11

38

The Lancet Haematology

@TheLancetHaem

7 months

NEW: results of the phase 2, dose optimisation study CULMINATE on cusatuzumab (anti-CD70 antibody) plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy #leusm

3

11

40

The Lancet Haematology

@TheLancetHaem

10 months

Our August issue is out! Packed with #sicklecell disease content: our Commission, a #GBD study on #sicklecell , and several associated pieces Also trials on AML, #HIV -related HL, and #menstrualbleeding in VWD #leusm #lymsm #bleedingdisorders ➡️

1

15

40

The Lancet Haematology

@TheLancetHaem

4 years

Edmund K Waller—Treatment landscape in DLBCL: New developments, and when to take the #CARTcell instead? Comprehensive overview of current management #lymsm #EBMT20Virtual

0

28

39

The Lancet Haematology

@TheLancetHaem

3 years

Our August issue is now live! Featuring research on #COVID19Vaccine in #hemonc patients, thresholds for iron deficiency, trials in AML/MDS and HL, and more! #anemia #leusm #mdssm #lymsm #mmsm For the Editors' highlights, visit

1

19

39

The Lancet Haematology

@TheLancetHaem

4 months

NEW online: First international consensus guidelines on the diagnosis and management of pyruvate kinase deficiency

0

16

43

The Lancet Haematology

@TheLancetHaem

4 years

NEW research—A systematic review and meta-analysis of 35 trials and 953 patients with acute lymphocytic leukaemia treated with anti-CD19 #CART -cell therapy #leusm

2

13

39

The Lancet Haematology

@TheLancetHaem

4 years

Our July issue is out! Featuring a pilot study integrating #sicklecell screening as part of immunisation programmes in Nigeria, trials in DLBCL and ALL, machine learning in #hemonc , a new #DiversityandInclusion column & more! #leusm #lymsm

2

21

38

The Lancet Haematology

@TheLancetHaem

5 years

Although CAR T-cell therapy shows a lot of promise for patients with haematological malignancies, there are still a lot of questions to be answered as raised by Prof Gauthier #IACH19

1

21

39

The Lancet Haematology

@TheLancetHaem

11 months

ICYMI: with over 5 years of follow-up, sorafenib maintenance is associated with improved outcomes compared w/ non-maintenance in patients w/ FLT3-ITD AML undergoing allogeneic HSCT in a multicentre, randomised, ph 3 trial #leusm #bmtsm

0

12

39

The Lancet Haematology

@TheLancetHaem

4 years

High-quality evidence showing the effectiveness of treatments for #COVID19 is scarce, but over 400 studies are now registered testing a range of therapies. Our May Editorial discusses the resurgence of covalescent #PlasmaTherapy

2

22

35

The Lancet Haematology

@TheLancetHaem

2 years

Our November issue is now live! Featuring Articles on therapies for multiple myeloma, fetal and neonatal alloimmune thrombocytopenia, and allogeneic CAR T cells in B-ALL, a Viewpoint on the impact of drug prices in CML, and much more. #mmsm #leusm

0

15

37

The Lancet Haematology

@TheLancetHaem

3 years

#EBMT21 Leo Luznik on the results of the BMT CTN 1301 trial comparing calcineurin inhibitor-free GVHD prophylaxis in HCT recipients who received myeloablative conditioning & had HLA-matched donors #bmtsm (1/2)

1

22

38

The Lancet Haematology

@TheLancetHaem

4 years

ICYMI: “Assessing venous thromboembolism and bleeding risks regularly is essential... we found that patients with COVID-19 with a high risk of venous thromboembolism had poorer outcomes” NEW—comment from China by Wang & colleagues #COVID19 #VTE #anticoag

3

32

37

The Lancet Haematology

@TheLancetHaem

6 months

Our first issue of 2024 is out! Featuring trials on MDS & #thrombosis , outcomes in CCUS, our Editorial on CRISPR/Cas9 #genetherapy , and more! 🎨Cover art by Sam Falconer inspired by the Review on bone marrow transplantation in #myelofibrosis #bmtsm

4

9

38

The Lancet Haematology

@TheLancetHaem

3 years

#EBMT21 . Carmem Bonfim tells us about haploidentical HSCT in Fanconi #anemia and their protocol adaptations in Brazil #BMFSM #BMTSM

4

13

36

The Lancet Haematology

@TheLancetHaem

4 years

It's #RareDiseaseDay ! Over 300 million people live with one of 6000 rare diseases globally and less than 5% have an approved therapy. To support the rarediseaseday campaign by @eurordis we have assembled a collection of comments & research on haematological rare diseases. Thread

1

30

37

The Lancet Haematology

@TheLancetHaem

3 years

NEW research—A retrospective study in 949 patients suggest hypomethylating agents are the preferred first-line therapy for patients with high-risk or myeloproliferative CMML #leusm

2

13

36

The Lancet Haematology

@TheLancetHaem

2 years

Clinical Quiz A man with HIV presents with haemolytic anaemia. Direct Coombs testing is negative. Peripheral blood smear shows neutrophil-erythrocyte rosettes. Medications include ART and prophylactic trimethoprim-sulfamethoxazole. What is the likely diagnosis and best next step?

1

9

37